A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : ADA / adalimumab

[Related PubMed/MEDLINE]
Total Number of Papers: 373
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   ADA  (>> Co-occurring Abbreviation)
Long Form:   adalimumab
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-alpha Inhibitor-naive and Non-naive Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease. CD, IFX, OR
2019 Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study. BCVA, DMARD
2019 Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry. ACR, AEs, JIA, MTX, SAEs
2019 An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients. bDMARD, csDMARDs, DAS28-CRP, mHAQs, MTX, RA
2019 Association of anti-cyclic citrullinated peptide antibody with clinical features in patients with psoriatic arthritis. CASPAR, DMARDs, ETN, IFX, PsA, RF, TNF
2019 Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. IFX, UME
2019 Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn's disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience. CD, CR, PCDAI
2019 Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity. DAPSA, MDA, PASDAS, PBO, TA
2019 Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. DLQI, HiSCR, HS, OLE, PRRs
10  2019 Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics. CD, IFX, LOR
11  2019 Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. IFX
12  2019 Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis. CZP, GLM
13  2019 Polarization of Rheumatoid Macrophages by TNF Targeting Through an IL-10/STAT3 Mechanism. bDMARDs, ETA, RA, RTX, TCZ
14  2019 Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. AZA, CD, EQ-5D, HRQoL
15  2019 Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. AS, CI, ETN, GISEA, HR, INF, IQR, PsA, SIs, SpA, TNF
16  2019 Regression of Optic Disc Neovascularization (NVD) in a Patient with Behcet's Disease Treated with Oral Corticosteroids and Adalimumab (ADA). ---
17  2019 Results of a retrospective study on the efficacy and safety of adalimumab 80mg administrated every other week in patients with psoriasis at a single Japanese institution. TNF
18  2019 Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases. IBD, IFX, SpA, TNFi
19  2019 Statement of the expert group on the current practice and prospects for the treatment of complex perirectal fistulas in the course of Crohn's disease. CD, CER, IFX
20  2019 Successful closure of ileostomy in a patient with intestinal Behcet's disease after therapy with adalimumab: A case report. BD
21  2019 Tocilizumab and the risk of respiratory adverse events in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised controlled trials. AEs, PBO, RCT, RR, SAEs
22  2018 Adalimumab drug and antidrug antibody levels do not predict flare risk after stopping adalimumab in RA patients with low disease activity. ---
23  2018 Adalimumab persistence for inflammatory bowel disease in veteran and insured cohorts. IBD, OR, VHA
24  2018 Adalimumab therapy in hepatitis B virus-negative polyarteritis nodosa: A case report. PAN
25  2018 Adalimumab-Based Treatment Versus Disease-Modifying Antirheumatic Drugs for Venous Thrombosis in Behcet's Syndrome: A Retrospective Study of Seventy Patients With Vascular Involvement. BS, DMARD
26  2018 Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis aHR, AMCs, ETN, IFX, UST
27  2018 An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective. ACR, ETN, MTX, PMPM, RA, TNFi
28  2018 Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants. anti-TNF, CZP, IFN-gamma, IFX
29  2018 Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type. IBD, IFX
30  2018 Anti-tumor necrosis factor agents in sarcoidosis: A systematic review of efficacy and safety. anti-TNFs, IFX, RCTs
31  2018 Clinical Responses and Synovial Vascularity in Obese Rheumatoid Arthritis Patients Treated with Adalimumab and Methotrexate. ACR, LDA, MTX, RA
32  2018 Clinical Utility of Serum Concentrations of Adalimumab as Predictor of Treatment Adherence. IA, IBD, MGT, MPR, Sc
33  2018 Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naive Crohn's Disease. CD, IFX
34  2018 Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases. ADAs, AS, CERT, ETA, GOL, HLA, IFX, PsA, RA
35  2018 Cumulative retention rate of adalimumab in patients with Behcet's disease-related uveitis: a four-year follow-up study. BD, DMARDs
36  2018 Defining an Optimal Adherence Threshold for Patients Taking Subcutaneous Anti-TNFs for Inflammatory Bowel Diseases. IBD, MPR
37  2018 Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate. MTX, TCZ, TOF
38  2018 Do Anti-TNF Agents Increase the Risk of Inflammatory Bowel Disease Evolution in Patients with Ankylosing Spondylitis? Real Life Data. AS, ETN, GO, IBD, INF, TNF
39  2018 Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study. ABT, bDMARDs, CZP, DAS28-ESR, ETN, GLM, IFX, RA, TCZ
40  2018 Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study. AI, ANOUVEAU, HM, OWI, PTW, PW, RA, WPAI/RA
41  2018 Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers. CI, IBD, UC
42  2018 Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial. HA, PGA, PhGA, VAS, WOMAC
43  2018 Efficacy and Safety of Adalimumab in Pediatric Ulcerative Colitis: A Real-life Experience from the SIGENP-IBD Registry. IFX, UC
44  2018 Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review. AEs, RCTs, VA
45  2018 Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1). ACR, EPP, IXE, PBO, PsA
46  2018 Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease. CD, ED, IFX, TNF-alpha
47  2018 Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. BCVA, cDMARDs, IFX, RV, TNF
48  2018 High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab. AUC, CI, MMP-3, OR, RA
49  2018 Impact of the Adalimumab Patient Support Program on Clinical Outcomes in Ankylosing Spondylitis: Results from the COMPANION Study. AC-PSP, AS, BASDAI, CCCs, RR, TNF
50  2018 Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study. CCCs, PSP
51  2018 Is Patient Support Program Participation Associated with Longer Persistence and Improved Adherence Among New Users of Adalimumab? A Retrospective Cohort Study. CHS, MPR, PSP
52  2018 Long-term safety and effectiveness of adalimumab for the treatment of Japanese patients with rheumatoid arthritis: 3-year results from a postmarketing surveillance of 552 patients. ADRs, PYs, RA, SADRs
53  2018 Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis. AE, IFX, JIA
54  2018 Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase III Trial. MTX, RA
55  2018 New adalimumab formulation associated with less injection site pain and improved motivation for treatment. ---
56  2018 Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. GOL, IFX, LOR, s.c, UC
57  2018 Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data. AP, CD, CDAI, PBO, SES-CD, SF
58  2018 Persistency of Biologic Therapies for Plaque Psoriasis in 2 Large Community Practices. ETA, IFX, UST
59  2018 Pharmacokinetic and pharmacodynamic model for analysis of adalimumab administered for Crohn's disease. CD, CDAI
60  2018 Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis. ACR20, PK, RA
61  2018 Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis Responding to Adalimumab plus Methotrexate vs Methotrexate Alone: A Placebo-controlled Clinical Trial. ACR/EULAR, miRNA, MTX, RA, ROC
62  2018 Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. CD, IBD, IFX, UC
63  2018 Postoperative adalimumab maintenance therapy for Japanese patients with Crohn's disease: a single-center, single-arm phase II trial (CCOG-1107 study). CD
64  2018 Protective effects of tumor necrosis factor alpha inhibitors on methotrexate-induced pancreatic toxicity. i.p, MTX
65  2018 Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-alpha biologicals and an Infliximab-biosimilar. GFP, IBD, IFX
66  2018 Randomized Controlled Study to Evaluate the Efficacy of Adalimumab in Patients with Different Forms of Refractory Uveitis. BCVA
67  2018 Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Varios Biologic DMARDs. bDMARDs, CDAI, CRP, csDMARD, ETN, GOL, RA, RTX, SDAI, TCL
68  2018 Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort. bDMARDs, ETN, IFX, IORRA, MTX, RA, TCZ
69  2018 Reply. BS, DMARDs
70  2018 Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience. anti-TNF, DAS28-CRP, ETN, HR, IFX, RA
71  2018 Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France). axSpA, ETN, HR, HR, IFX, TNF
72  2018 Simultaneous Quantification of Adalimumab and Infliximab in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry. IFX, TNF-alpha
73  2018 Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behcet's Disease. BD
74  2018 Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results. RA
75  2018 The Efficacy and Safety of Mainstream Medications for Patients With cDMARD-Naive Rheumatoid Arthritis: A Network Meta-Analysis. ACR, cDMARDs, CrI, ETN, GOL, IFX, MTX, ORs, RA, RCTs, SUCRA, TCZ
76  2018 The prevalence and clinical effect of immunogenicity of TNF-alpha blockers in patients with axial spondyloarthritis. ASDAS-CRP, BASDAI, ETN, INF, SpA
77  2018 Therapeutic Drug Monitoring Guides the Management of Crohn's Patients with Secondary Loss of Response to Adalimumab. CD, LOR, SL, TDM
78  2018 Whole-body Magnetic Resonance Imaging in Axial Spondyloarthritis: Reduction of Sacroiliac, Spinal, and Entheseal Inflammation in a Placebo-controlled Trial of Adalimumab. axSpA, BASDAI, MRI, SDC
79  2018 [A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for pediatric Crohn's disease]. CD, IFX
80  2017 A disintegrin and metalloproteinase (ADAM)-10 as a predictive factor for tocilizumab effectiveness in rheumatoid arthritis. ADAM, RA, TCZ
81  2017 A Meta-Analysis of Adalimumab for Fistula in Crohn's Disease. CD, N-RCTs, rcts
82  2017 Adalimumab and postoperative complications of elective intestinal resections in Crohn's disease: a propensity score case-matched study. CD, PSM
83  2017 Adalimumab effectiveness in Behcet's disease: short and long-term data from a multicenter retrospective observational study. BD, TNF
84  2017 Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study. ASDAS-CRP, BASDAI, BASFI, BASMI, CDAI, ES, HAQ, HRQoL, IBDQ, PGA, pMayo, PROs, SF-36, TNF
85  2017 Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn's disease. CD, IFX, MH, PCDAI, SES-CD, TNF
86  2017 Adalimumab for the treatment of refractory noninfectious paediatric uveitis. SUN
87  2017 Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial. AZA, POR-CD, s.c
88  2017 Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database. CZP, ETA, GLM, SC-TNFis
89  2017 Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-alpha (TNF-alpha) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015. ETN, FAERS, ISR, MTX, QOL, RA, RORs, TNF-alpha
90  2017 Anti-TNFalpha therapy and switching in severe uveitis related to Vogt-Koyanagi-Harada syndrome. ---
91  2017 Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. DAS28rem, RA
92  2017 Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. bsIFX, ICURs, IFX, QALYs, VEDO
93  2017 Discontinuation of long-term adalimumab treatment in patients with juvenile idiopathic arthritis-associated uveitis. JIAU
94  2017 Disease Status and Pubertal Stage Predict Improved Growth in Antitumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease. IFX, PIBD, TNF
95  2017 Does long-term efficacy differ between infliximab and adalimumab after 1 year of continuous administration?: A STROBE-compliant retrospective cohort study. CD, CI, CRP, IFX, LOR, OR
96  2017 Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study. ETN, IFX, RA
97  2017 Dose escalation of biologics in Crohn's disease: critical review of observational studies. CD, IFX
98  2017 Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. CI, EQ-5D-5L, HRQL, SCCAI, SD, SIBDQ, UC, VAS
99  2017 Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients. AE, CRP, FC, UC
100  2017 Effectiveness of early adalimumab therapy in psoriatic arthritis patients from Reuma.pt - EARLY PsA. csDMARD, DAS28, HAQ-DI, PhGA, PsA, PsARC, Reuma.pt